Novartis’ high blood pressure medicine Rasilez (aliskiren) will become available in Japan after the drug received approval from the Japanese health department.
Rasilez directly inhibits renin, an enzyme that triggers a process leading to high blood pressure and organ damage.
The Ministry of Health, Labour and Welfare (MHLW) in Japan has approved Rasilez for the treatment of high blood pressure, alone or in combination with other high blood pressure medicines.
The potential long-term benefits of Rasilez are still being investigated in the ASPIRE HIGHER programme, which involves more than 35,000 patients in 14 trials.
Novartis global head of development Trevor Mundel said that the company was excited about the approval in Japan.
“This provides Japanese patients with access to this innovative high blood pressure treatment that directly targets rennin,” Mundel said.
Rasilez, also known as Tekturna, has been approved in over 70 countries.